Skip to main content Accessibility help

Serum cytokine profile of laryngeal squamous cell carcinoma patients

  • J Sotirović (a1), A Perić (a1), D Vojvodić (a2), N Baletić (a1), I Zaletel (a3), I Stanojević (a2), M Erdoglija (a1) and M Milojević (a1)...



This study aimed to evaluate serum cytokine concentrations in healthy individuals and laryngeal squamous cell carcinoma patients.


A total of 59 laryngeal squamous cell carcinoma patients and 44 healthy controls were included. Multiplex analysis of interleukins 2, 4, 5, 6, 10, 12, 13 and 17 and interferon-gamma with respect to the presence of laryngeal carcinoma, tumour–node–metastasis T stage, nodal involvement and larynx subsite was performed.


Statistical analysis revealed no difference in serum cytokine levels between patients and healthy controls. The serum interleukin-12 concentration was significantly higher in patients with early (T1–2) than in those with late (T3–4) stage disease and without nodal involvement (p < 0.05). Serum interleukin-10 levels were significantly higher in T3–4 stage than in T1–2 stage patients (p < 0.05). Additionally, serum interleukin 10, 12 and 13 concentrations (p < 0.05) and interleukin-6 concentration (p < 0.01) were significantly higher in patients with T1–2 stage supraglottic vs glottic tumours.


Serum cytokines level cannot be used as laryngeal squamous cell carcinoma markers. Progression from T1–2 to T3–4 stage is followed by decreased serum interleukin-12 levels and increased interleukin-10 levels. Nodal involvement is associated with lower serum interleukin-12 levels. In patients with early stage tumours, serum interleukin 6, 10, 12 and 13 concentrations are significantly higher in those with supraglottic vs glottic tumours.


Corresponding author

Address for correspondence: Dr J Sotirović, Kaplara Momčila Gavrića 2, 11000 Belgrade, Serbia Fax: +381 11 2666 164 E-mail:


Hide All
1 Wan, YY. Multi-tasking of helper T cells. Immunology 2010;130:166–71
2 Yang, B, Kang, H, Fung, A, Zhao, H, Wang, T, Ma, D. The role of interleukin 17 in proliferation, angiogenesis, and metastasis. Mediators Inflamm 2014;2014:623759
3 Zhang, X, Weng, W, Xu, W, Wang, Y, Yu, W, Tang, X et al. Prognostic significance of interleukin 17 in cancer: a meta-analysis. Int J ClinExp Med 2014;7:3258–69
4 Candido, J, Hagemann, T. Cancer-related inflammation. J Clin Immunol 2013;33(suppl 1):S79–84
5 Lin, WW, Karin, M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175–83
6 Becker, Y. Molecular immunological approaches to biotherapy of human cancers – a review, hypothesis and implications. Anticancer Res 2006;26:1113–14
7 Albers, AE, Strauss, L, Liao, T, Hoffmann, TK, Kaufmann, AM. T-cell tumor interaction directs the development of immunotherapies in head and neck cancer. Clin Dev Immunol 2010;2010:236378
8 Bleotu, C, Chifiriuc, MC, Grigore, R, Grancea, C, Popescu, CR, Anton, G et al. Investigation of Th1/Th2 cytokine profiles in patients with laryngo-pharyngeal, HPV-positive cancers. Eur Arch Otorhinolaryngol 2013;270:711–18
9 Eyigor, M, Eyigor, H, Osma, U, Yilmaz, MD, Erin, N, Selcuk, OT et al. Analysis of serum cytokine levels in larynx squamous cell carcinoma and dysplasia patients. Iran J Immunol 2014;11:259–68
10 Günaydin, , Kesikli, SA, Kansu, E, Hoşal, . Identification of the peripheral blood levels of interleukin-12, interleukin-10, and transforming growth factor-β in patients with laryngeal squamous cell carcinoma. Head Neck 2012;34:393–7
11 Edge, S, Byrd, DR, Compton, CC, Fritz, AG, Greene, FL, Trotti, A, eds. AJCC Cancer Staging Manual, 7th edn. New York: Springer; 2009
12 Schilling, B, Halstead, ES, Schuler, P, Harasymczuk, M, Eqan, JE, Whiteside, TL. IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients. Cancer Immunol Immunother 2012;61:1395–405
13 Vesely, MD, Kershaw, MH, Schreiber, RD, Smyth, MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235–71
14 Kim, HJ, Cantor, H. CD4 T-cell subset and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res 2014;2:91–8
15 Young, MR. Protective mechanisms of head and neck squamous cell carcinoma from immune assault. Head Neck 2006;28:462–70
16 Müller-Hübenthal, B, Azemar, M, Lorenzen, D, Huber, M, Freudenberg, MA, Galanos, C et al. Tumour biology: tumour-associated inflammation versus antitumor immunity. Anticancer Res 2009;29:4795–806
17 Allen, CT, Judd, NP, Bui, JD, Uppaluri, R. The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope 2012;122:144–57
18 Millrud, CR, Hylander, T, Kumlien Georen, S, Kågedal, Å, Winqvist, O, Cardell, LO. Inverse immunological responses induced by allergic rhinitis and head and neck squamous cell carcinoma. PLoS One 2014;9:e86796
19 Hoffmann, TK, Sonkoly, E, Homey, B, Scheckenbach, K, Gwosdz, C, Bas, M et al. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck. Head Neck 2007;29:472–8
20 Hathaway, B, Landsittel, DP, Gooding, W, Whiteside, TL, Grandis, JR, Siegfried, JM et al. Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck. Laryngoscope 2005;115:522–7
21 Jebreel, A, Mistry, D, Loke, D, Dunn, G, Hough, V, Oliver, K et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol 2007;121:246–52
22 Lathers, DM, Achille, NJ, Young, MR. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 2003;64:1160–6
23 Kaskas, NM, Moore-Medlin, T, McClure, GB, Ekshyyan, O, Vanchiere, A, Nathan, CA. Serum biomarkers in head and neck squamous cell cancer. JAMA Otolaryngol Head Neck Surg 2014;140:511
24 Pai, SI, Westra, WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis and treatment. Annu Rev Pathol 2009;4:4970
25 Westra, WH. The changing face of head and neck cancer in the 21st century: The impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol 2009;3:7881
26 Melinceanu, L, Lerescu, L, Tucureanu, C, Caras, I, Pitica, R, Sarafoleanu, C et al. Serum perioperative profile of cytokine in patients with squamous cell carcinoma of the larynx. J Otolaryngol Head Neck Surg 2011;40:143–50
27 Green, VL, Michno, A, Green, J, Stafford, ND. Effect of treatment on systemic cytokines in head and neck squamous cell carcinoma patients. Results Immunol 2012;2:16
28 Zundler, S, Neurath, MF. Interleukin-12: Functional activities and implications for disease. Cytokine Growth Factor Rev 2015;26:559–68
29 Sorensen, EW, Gerber, SA, Frelinger, JG, Lord, EM. IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-γ–dependent mechanisms. J Immunol 2010;184:1858–66
30 Liang, W, Wang, XF. In vitro induction of specific anti-tumoral immunity against laryngeal carcinoma by using human interleukin-12 gene-transfected dendritic cells. Chin Med J (Engl) 2011;124:1357–61
31 Tian, L, Chen, X, Sun, Y, Liu, M, Zhu, D, Ren, J. Growth suppression of human laryngeal squamous cell carcinoma by adenoviral-mediated interleukin-12. J Int Med Res 2010;38:9941004
32 Geginat, J, Larghi, P, Paroni, M, Nizzoli, G, Penatti, A, Pagani, M et al. The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer. Cytokine Growth Factor Rev 2016;30:8793
33 Zhou, J, Zhang, D, Chen, B, Li, Q, Zhou, L, Liu, F et al. Association of interleukin-10 promoter polymorphisms and corresponding plasma levels with susceptibility to laryngeal squamous cell carcinoma. Oncol Lett 2014;7:1721–7
34 Qian, X, Chen, H, Wu, X, Hu, L, Huang, Q, Jin, Y. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine 2017;89:3444
35 Meng, CD, Zhu, DD, Jiang, XD, Li, L, Sha, JC, Dong, Z et al. Overexpression of interleukin-l7 in tumor-associated macrophages is correlated with the differentiation and angiogenesis of laryngeal squamous cell carcinoma. Chin Med J (Engl) 2012;125:1603–7
36 Kopta, R, Mochocki, M, Morawski, P, Brzezińska-Blaszczyk, E, Lewy-Trenda, I, Student Scientific Circle et al. Expression of Th17 cell population regulatory cytokines in laryngeal carcinoma – preliminary study. Contemp Oncol (Pozn) 2015;19:195200
37 Mor, N, Blitzer, A. Functional anatomy and oncologic barriers of the larynx. Otolaryngol Clin North Am 2015;48:533–45
38 Ozdek, A, Sarac, S, Akyol, MU, Unal, OF, Sungur, A. Histopathological predictors of occult lymph node metastases in supraglottic squamous cell carcinomas. Eur Arch Otorhinolaryngol 2000;257:389–92
39 Nikakhlagh, S, Ranjbari, N, Khorami, E, Saki, N. Association between serum levels of interleukin-6 and stage of laryngeal cancer. Iran J Otorhinolaryngol 2015;27:199205
40 Mojtahedi, Z, Khademi, B, Hashemi, SB, Abtahi, SM, Ghasemi, MA, Fattahi, MJ et al. Serum interleukin-6 concentration, but not interleukin-18, is associated with head and neck squamous cell carcinoma progression. Pathol Oncol Res 2011;17:710
41 Hao, W, Zhu, Y, Zhou, H. Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer. Med Oncol 2013;30:333
42 Shkeir, O, Athanassiou-Papaefthymiou, M, Lapadatescu, M, Papagerakis, P, Czerwinski, MJ, Bradford, CR et al. In vitro cytokine release profile: predictive value for metastatic potential in head and neck squamous cell carcinoma. Head Neck 2013;35:1542–50
43 Whiteside, TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904–12



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed